Branded vs. compounded GLP-1s: what the evidence says

What did @drrekhakumar actually say?

The creator, who identifies as an endocrinologist, walked through what patients should watch for when switching from a branded GLP-1 (like Ozempic or Wegovy) to a compounded version. The core points: compounded GLP-1s are not FDA-approved, there are no formal comparative efficacy studies, potency may differ, and patients should verify that their compounding pharmacy does third-party testing. She specifically told viewers to ask, "do they test for potency?" and to monitor whether they feel "the same as you did on your branded." This is practical, patient-facing guidance, not a deep pharmacology lecture. Worth noting: she did not claim compounded versions are equivalent, and she did not recommend any specific product or dose. That restraint matters in this space.

Does the science back this up?

On the FDA status and lack of comparative studies, she is correct. The evidence on compounded semaglutide or tirzepatide efficacy is essentially nonexistent in peer-reviewed literature. The branded drugs earned their approvals through large, controlled trials, including the SUSTAIN and STEP programs for semaglutide and the SURMOUNT trials for tirzepatide. No equivalent trials exist for compounded versions.

The concern about potency is legitimate but more complex than the video conveys. A 2023 analysis by the FDA flagged multiple compounding pharmacies producing semaglutide products with inaccurate dosing, impurities, or incorrect salt forms (the base vs. acetate vs. sodium salt issue). The American Society of Health-System Pharmacists has also raised concerns about variability in compounded injectable peptides. Third-party testing is a real and meaningful safeguard, and it is genuinely underused in this market. Her suggestion to ask pharmacies directly about testing protocols is sound, practical advice.

What did they get wrong (or right)?

She got the headline right: compounded GLP-1s carry real unknowns, and the absence of FDA approval means there is no guaranteed standardization of potency, sterility, or stability. That is not a scare tactic. It is the regulatory reality.

Where the video falls short is the framing around "active pharmaceutical ingredients." She says, "being that we don't know about some of the active pharmaceutical ingredients of the compounded versions." This is a bit muddled. The active ingredient in compounded semaglutide is, in most cases, semaglutide, but the issue is the salt form. The FDA has specifically warned that semaglutide sodium and semaglutide acetate are not the same as semaglutide base, the form used in Ozempic and Wegovy. This distinction is clinically meaningful and was omitted. A 2024 FDA safety communication noted adverse event reports linked to compounded semaglutide products, some tied to dosing errors or incorrect formulations.

She also frames potency monitoring entirely around subjective appetite control, which is reasonable but incomplete. Patients could feel similar appetite suppression at a lower dose due to adaptation, not equivalent potency. Objective monitoring, like weight trajectory, would strengthen that guidance.

What should you actually know?

If you are considering or already using a compounded GLP-1, here is what the evidence actually supports. The FDA removed semaglutide from its drug shortage list in 2024, which legally restricts most compounding pharmacies from producing copies of FDA-approved drugs like Ozempic and Wegovy under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. That regulatory landscape is shifting fast, and access to compounded versions may change depending on legal challenges and shortage designations.

Third-party testing is not optional if you are using a compounded injectable. Ask specifically whether the pharmacy tests for:

• Potency (is the labeled dose what is actually in the vial)
• Sterility (injectable products carry infection risk if improperly prepared)
• Absence of impurities or degradation products

The creator's suggestion to call the pharmacy directly is a low-bar but real first step. PCAB (Pharmacy Compounding Accreditation Board) accreditation is another marker worth asking about. Finally, talk to your prescribing provider before switching, not after. This video is useful context, but it is not a substitute for a clinical conversation about your specific situation.